Product menu

SHINGRIX: Recommendations from CIQ

CIQ Recommendations

Checkmark icon

The Comité sur l’immunisation du Québec (CIQ) recommends that authorized healthcare professionals in Quebec:1

Must recommend vaccination to immunocompromised adults 18 years of age and older.

Must recommend vaccination to adults 75 years of age and older.

Must inform adults 50 years of age and older that they are eligible for vaccination.

To view the complete CIQ recommendations, click here.

Graph icon

Efficacy data for SHINGRIX2

Vaccine efficacy profile was studied in subjects ≥50 years old (ZOE-50) and subjects ≥70 years old (ZOE-70). SHINGRIX efficacy profile was also studied in two immunocompromised patient populations aged ≥18 years.2

Learn more
Patient icon

Start the conversation about shingles risk with your patients

Nearly everyone ≥50 years old should be protected against shingles.3

Learn more
Vaccine icon

Find out about SHINGRIX dosing and administration

Discover more about administering the vaccine and discussing shingles and vaccination with your patients.

Learn more

References:

  1. Reproduction of information from the PIQ, Zona-SU section. Available at: http://www.msss.gouv.qc.ca/professionnels/vaccination/piq-vaccins/zona-su-vaccin-sous-unitaire-contre-le-zona/. Accessed May 6, 2024.
    The original French version of this information was published in 2023 by the Department of Health and Social Services. The Dept. declines any responsibility for any damage, loss, or injury that may result from this translation into English. In case of contradiction between the English and French versions of this information, the latter will prevail. The Government of Quebec is and remains the only copyright owner of the work in French. The English version has not been validated by the Ministry of Health and Social Services.
  2. SHINGRIX Product Monograph. GlaxoSmithKline Inc., November 15, 2022.
  3. Public Health Agency of Canada. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) – Updated Recommendations on the Use of Herpes Zoster Vaccines. Ottawa, Ontario: Public Health Agency of Canada; June 2018. Available at: https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html. Accessed November 30, 2022.

Trademarks are owned by or licensed to the GSK group of companies.

©2024 GSK Group of companies or its licensor.

10572 | 05/24